Health and Healthcare
GlobeImmune Files For IPO, Cancer & Hepatitis with Great Partnerships
Published:
Last Updated:
GlobeImmune, Inc. is the latest biotech to file for an initial public offering. Financial terms were not disclosed but the first filing is for up to $69 million in common stock. This one has partnerships with Celgene Corporation (NASDAQ: CELG) and Gilead Sciences, Inc. (NASDAQ: GILD) and has five candidates under various stage trials.
Celgene is a 16% owner, Healthcare Ventures is a 14% owner, Morgenthaler is a 14% owner, and Lilly Ventures has more than a 6% stake and that is a $200 million fund tied originally to Eli Lilly & Co. (NYSE: LLY).
Book runners are listed as Wells Fargo Securities and Piper Jaffray, with JMP Securities as a co-manager.
The company description: “We are a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases based on our proprietary Tarmogen® platform. Tarmogens activate the immune system by stimulating cellular immunity, known as T cell immunity, in contrast to traditional vaccines, which predominately stimulate antibody production. We have four Tarmogen product candidates in five ongoing clinical trials.”
GlobeImmunue’s lead cancer product candidate, GI-4000, is being evaluated in combination with gemcitabine in a fully-enrolled, placebo-controlled Phase 2b trial in resected pancreas cancer. Its lead infectious disease product candidate, GI-5005, has completed a randomized, active-control Phase 2b trial in chronic hepatitis C virus, or HCV, infection.
GlobeImmune has two strategic collaborations, one with Celgene Corporation for all oncology product candidates and one with Gilead Sciences, Inc. for chronic hepatitis B virus, or HBV, infection.
Of course this company is pre-revenue so it has nothing but losses to show to date.
JON C. OGG
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
